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INTRODUCTION
No reliable screening method for donated blood
had been established before 1972. The incidence of
post-transfusion hepatitis was very high (20-40%)
before that year (1). HBs antigen measurement was
introduced in 1972 as a means of screening blood donated
for transfusion. Since 1981, alanine aminotransferase
(ALT) activity measurement has been additionally
performed to check donated blood, resulting in a
reduction in the incidence of post-transfusion hepa-
titis (2). However, non-A, non-B post-transfusion hepa-
titis was still seen in about 15% of blood recipients.
Under these circumstances, serum guanase (gua-
nine deaminase ;GU) measurement began to attract
attention as a more effective means of screening
donated blood (3-5).
GU is abundantly expressed in the liver, brain and
kidney. It is quite scarce in the skeletal muscles,
myocardium, pancreas and other organs in which
aspartate aminotransferase (AST) and ALT are rela-
tively abundant (6-7). Therefore, it has been report-
ed that a rise in blood GU activity may be a sign
specific to liver disease, and that measurement of
his enzyme may serve as an excellent means of
screening for liver disease (8-10). It has also been
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shown that the GU activity in transfused blood is signifi-
cantly correlated with the incidence of post-transfusion
hepatitis (3-5), and that discarding donated blood
showing high GU activity can reduce the incidence
of post-transfusion hepatitis (11). Based on these
findings, the introduction of GU measurement as a
screening test for blood donated for transfusion
was discussed. However, in 1989, a method for
measuring hepatitis C virus (HCV) antibody was
published (12), which hampered the introduction
of GU measurement as a screening test for donated
blood.
In November 1989, checking donated blood for
HCV antibody (C100-3 antibody) and HBc antibody
was started. Since then, a sharp decrease in the in-
cidence of post-transfusion hepatitis has been re-
ported. Since February 1992, when second-generation
HCV antibody measurement was introduced, the
incidence of post-transfusion hepatitis has decreased
to almost zero (13-15). Data collected from HCV
antibody measurements revealed that most cases
of post-transfusion non-A, non-B hepatitis were cases
of hepatitis C. Therefore, it was thought that there
could be some relationship between the serum GU
activity and hepatitis C. To date, however, this re-
lationship has not been studied. After the introduc-
tion of HCV antibody measurement, the signifi-
cance of GU measurement has to be revealed.
The present study was undertaken to follow the
time-course of changes in the serum GU activity in
patients with hepatitis, and to examine the clinical
significance of serum GU activity measurement in
patients with hepatitis C.
SUBJECTS AND METHODS
Subjects
Of the patients who visited our department be-
tween January 1991 and December 1996, 688 pa-
tients in whom either serum ALT activity was ab-
normal, or in whom HBsAg or HCVAb was detect-
ed in the serum, were enrolled into this study.
Fig. 1 shows the clinical details of these subjects.
Elevated serum ALT activity was seen in 599 cases,
HBsAg was positive in 91 cases, and HCVAb was
positive in 436 cases. Thus, many patients had two
or more of the three abnormalities. The subjects
underwent biochemical tests and diagnostic imaging.
Biopsy was additionally performed in some of the
subjects. Based on the results, the subjects were
diagnosed as being asymptomatic carriers (ASC),
or as having chronic hepatitis (CH), liver cirrhosis
(LC) or hepatocellular carcinoma (HCC) ; of all the
subjects, 36 were diagnosed as being ASC, 372 as
having CH, 130 as having LC, 53 as having HCC,
and 116 as having “other disease”. In those patients
in whom liver biopsy was not performed, the diag-
nosis of ASC, CH, LC or HCC was made based on
the following criteria. The diagnosis of ASC was
made in cases where the serum ALT activity had
never been abnormal. The diagnosis of CH was
made in cases where the serum ALT activity had
remained abnormal for 6 months or longer, but the
criteria for diagnosis of LC and HCC were not sat-
isfied. The diagnosis of LC was made in cases where
three or more of the following criteria were satisfied,
and diagnostic imaging also indicated signs of LC :
1) serum AST/ALT ratio>1.0, 2) serum cholinesterase
activity (ChE) below 0.50△pH, 3) serum albumin
level (Alb) below 3.5 g/dl, 4) blood platelet count
(Plt) below 100,000/ml, 5) serum hepaplastin ac-
tivity (HPT) below 70%, and 6) ICG R15 over 15%.
The diagnosis of HCC was made in cases where
diagnostic imaging (abdominal ultrasonography, dy-
namic CT, or angiography) revealed signs sugges-
tive of HCC. The diagnosis of “other disease” was
made in cases where none of the aforementioned
liver conditions were diagnosed. The subjects were
divided into the HBsAg-positive group (HBV group,
excluding patients who were both HBsAg-and
HCVAb-positive), the HCVAb-positive group (HCV
Fig. 1. The clinical details of the subjects (total : 688 cases)
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group, excluding patients who were both HBsAg-
and HCVAb-positive), the HBsAg + HCVAb-positive
group (comprising patients who were both HBsAg-
and HCVAb-positive), and the HBsAg, HCVAb-negative
group (the NBNC group), as shown in Table 1. Of
all the patients, 90 were assigned to the HBV group,
449 patients to the HCV group, 3 patients to the
HBsAg + HCVAb-positive group, and 165 patients
to the NBNC group. During long-term follow-up,
CH progressed to LC in 7 cases, CH advanced to
HCC in 1 case, and LC progressed to HCC in 11
cases. These 19 cases were counted in duplicate.
For each of the followed up cases, hematological
testing was conducted once every 1-6 months. When
reporting the results, the number of cases was ex-
pressed as N, and the number of samples as n.
Measurement
HBs antigen was measured by the reversed pas-
sive hemagglutination (R-PHA) method ; HCV anti-
body was measured by enzyme immunoassay (EIA) ;
ChE was measured by the enzyme method ; Alb
was measured by bromcresol green (BCG) ; HPT
was measured automatically with an MDA ; AST
and ALT were measured by ultraviolet (UV) ; GU
was measured by the enzyme method, using a Hitachi
736 automated analyzer.
Methods
1) Correlation between serum ALT and serum GU
activity
For all samples (n=3744) obtained from 688 pa-
tients (707 cases, including duplicate counts), the
correlation between the serum ALT and serum GU
activity was evaluated. For each disease group, the
correlation between the two was analyzed by fur-
ther subdividing the group into the HBV group and
HCV group.
2) Analysis of cases not showing a relationship be-
tween the serum ALT and serum GU activity
The percentage of cases in which the serum ALT
activity was high while the serum GU activity was
normal was compared between the HBV group and
the HCV group, and also among the different dis-
ease groups. Then, the percentage of cases with
normal serum ALT activity but elevated serum GU
activity was compared between the HBV and the
HCV groups. Patients with chronic hepatitis C in
whom a normal ALT activity was recorded at least
once during the follow-up period were deemed as
cases showing normal ALT activity. The incidence
of elevated GU activity during periods of normal ALT
activity was investigated in these patients.
3) Testing the significance of differences
The F-test was used to test the coefficient of cor-
Table 1. Incidence of HBV and HCV in patients with liver disease
ASC CH LC HCC Another Total
B(+)C(-) 11 58 9
(10)
from CH : 1 case
7
(8)
from LC : 1 case
3 88
(90)
B(-)C(+) 25 310 70
(76)
from CH : 6 cases
25
(35)
from CH : 1 case
from LC : 9 cases
3 433
(449)
B(+)C(+) 0 1 1 1 0 3
B(-)C(-) 0 3 43 8
(9)
from LC : 1 case
110 164
(165)
Total 36 372 123
(130)
41
(53)
116 688
(707)
(counted in duplicate)
B : HBV C : HCV
ASC : asymptomatic carrier CH : chronic hepatitis LC : liver cirrhosis HCC : hepatocellular carcinoma
B(+)C(-) : HBV group
B(-)C(+) : HCV group
B(-)C(-) : NBNC group
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relation. P<0.05 was regarded as denoting statisti-
cal significance. Fisher’s exact test was employed
to test the percentage of cases not showing any
correlation between the serum ALT and serum GU
activity, and Student’s t-test was used for other tests.
P<0.01 was regarded as denoting significance in
these tests.
RESULTS
1) Correlation between the serum ALT and serum
GU activity
Table 2 shows the coefficient of correlation be-
tween the serum ALT and serum GU activity and
the p value for all samples (n=3744) obtained from
688 patients (707 cases if some patients were counted
in duplicate). For the entire population, a significant
correlation was observed between the ALT and GU
activity (r=0.872, p<0.0001). When analyzed by dis-
ease, a significant (p<0.0001) correlation between
the serum ALT and GU activity was observed in the
CH group (r=0.756), the LC group (r=0.662), the HCC
group (r=0.944) and the “other disease” group (r=
0.918). Favorable correlation were observed among
the HCC group and the “other disease” group. When
analyzed by the type of virus, the correlation be-
tween the ALT and GU activity was significantly
stronger (p<0.05) in the HCV group (r=0.891) than
in the HBV group (r=0.756). Among patients with
CH, the correlation was less strong in the HCV
group (r=0.747) than in the HBV group (r=0.854),
while among patients with HCC, the correlation
tended to be stronger in the HCV group (r=0.946)
than in the HBV group (r=0.816). However, none
of these differences between the HBV and the HCV
groups was statistically significant.
2) Analysis of cases not showing any correlation
between the serum ALT and serum GU activity
Fig. 2 shows the percentage of cases not show-
ing any correlation between the serum ALT and
serum GU activity in each virus-type group. The
overall percentage of cases with normal serum ALT
activity but elevated serum GU activity was 11.4%.
This percentage was higher in the HCV group
(12.2%) than in the HBV group (4.4%), although this
difference was not significant. The overall percent-
age of cases with elevated serum ALT activity but
normal serum GU activity was 30.4%. This percent-
age was higher in the HBV group (34.4%) than in the
HCV group (29.2%), although the difference was not
statistically significant. In both the HBV and the HCV
groups, the percentage of cases with normal serum
ALT activity but elevated serum GU activity was
significantly lower than the percentage of cases with
elevated serum ALT activity and normal serum GU
activity.
We then conducted a disease-wise analysis of the
percentage of cases with elevated serum ALT activ-
ity but normal serum GU activity (Table 3). There
was no significant difference in this percentage be-
tween the HBV and the HCV groups. In the HCV
group, this percentage was significantly higher in
patients with CH (38.4%) than in those with LC or
HCC. In the HBV group also, this percentage was
lower in patients with LC or HCC than in patients
Table 2. The coefficient of correlation between the serum ALT and serum GU activity and the p value for all samples (n=3744)
HBV group
(n=414)
HCV group
(n=2474)
B+C+
(n=8)
NBNC group
(n=848)
Total
(n=3744)
CH
(n=2198)
r=0.854
p<0.0001
r=0.747
p<0.0001
r=1.000
p=0.0183
r=0.899
p<0.0001
r=0.756
p<0.0001
LC
(n=720)
r=0.663
p<0.0001
r=0.648
p<0.0001
r=0.945
p<0.0001
r=0.758
p<0.0001
r=0.662
p<0.0001
HCC
(n=340)
r=0.816
p<0.0001
r=0.946
p<0.0001
r=0.715
p=0.0008
r=0.887
p<0.0001
r=0.944
p<0.0001
Another
(n=486)
r=0.965
p<0.0001
r=0.950
p<0.0001
r=0.916
p<0.0001
r=0.918
p<0.0001
Total
(n=3744)
＊
r=0.756
p<0.0001
r=0.891
p<0.0001
r=0.253
p=0.1943
r=0.914
p<0.0001
r=0.872
p<0.0001
＊ : p<0.05
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with CH, similar to the relationship observed in the
HCV group ; the difference between the two groups
was not statistically significant.
The percentage of cases with normal serum ALT
activity but elevated serum GU activity was also ana-
lyzed disease-wise (Table 4). Among patients with
CH, this percentage was significantly higher in the
HCV group (9.7%) than in the HBV group (0.0%). In
both the HBV and the HCV groups, this percentage
tended to increase as the underlying disease ad-
Fig. 2. The percentage of cases not show-
ing any correlation between the serum
ALT and serum GU activity in each virus-type
group
The overall percentage of cases with
normal serum ALT activity but elevated
serum GU activity was 11.4%. The over-
all percentage of cases with elevated se-
rum ALT activity but normal serum GU
activity was 30.4%. In both the HBV and
the HCV groups, the percentage of cases
with normal serum ALT activity but elevated
serum GU activity was significantly lower
than the percentage of cases with elevated
serum ALT activity and normal serum
GU activity.
(＊＊ : p<0.0001)
Table 3. A disease-wise analysis of the percentage of cases with elevated serum ALT activity but normal serum GU activity
ASC CH LC HCC other disease mean
HBV group 0.0%
(0/11)
NS
NS
49.2%
(29/58)
10.0%
(1/10)
12.5%
(1/8)
0.0%
(0/3)
34.4%
(31/90)
HCV group 0.0%
(0/25)
＊
＊
38.4%
(119/310)
9.2%
(7/76)
11.4%
(4/35)
3.6%
(1/3)
29.2%
(131/449)
NS : not significant
＊ : p<0.05
(counted in duplicate)
Table 4. The percentage of each cases
(cases with normal serum ALT activity but elevated serum GU activity analyzed disease-wise in HBV and HCV groups,
cases with normal serum ALT activity and cases with normal ALT but elevated serum GU activity in HCV group)
ASC CH LC HCC other disease mean
HBV group 0.0%
(0/11)
0.0%
(0/58)
18.2%
(2/10)
25.0%
(2/8)
0.0%
(0/3)
4.4%
(4/90)
HCV group 4.0%
(1/25)
＊
9.7%
(30/310)
18.4%
(14/76)
28.6%
(10/35)
0.0%
(0/3)
12.2%
(55/449)
normal ALT activity
in HCV group
100.0%
(25/25)
61.6%
(191/310)
46.1%
(35/76)
54.3%
(19/35)
33.3%
(1/3)
60.4%
(271/449)
normal ALT but elevated GU
activity in HCV group
4.0%
(1/25)
15.7%
(30/191)
40.0%
(14/35)
52.6%
(10/19)
0.0%
(0/1)
20.3%
(55/271)
*p<0.01 (counted in duplicate)
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vanced from CH to LC or from LC to HCC, but the
change was not statistically significant.
3) Analysis of cases with normal serum ALT activ-
ity
In the HCV group, we analyzed the percentage
of cases with normal serum ALT activity and the
percentage of cases with normal ALT but elevated
serum GU activity (Table 4). Of the 449 HCV-positive
cases, 60.4% had normal ALT activity. Of these cases,
20.3% had elevated serum GU activity, while the
serum ALT activity was normal. This percentage
tended to increase as the disease advanced, how-
ever, the change was not statistically significant.
DISCUSSION
Guanase is an enzyme that was first detected in
rabbit liver homogenates by Schmidt in 1932. In
1963, Passananti found that the serum guanase ac-
tivity rose in patients with liver disease. Since then,
guanase has been utilized in liver function testing,
and its relationship to post-transfusion hepatitis has
recently attracted close attention. In 1989, HCV anti-
body was detected (12), and some relationship be-
tween hepatitis C and serum GU activity was sug-
gested. Thereafter, however, no report on this re-
lationship has been published.
Under these circumstances, the present study
was undertaken to examine the relationship between
the serum GU and serum ALT activity in patients
with hepatitis, and to examine the clinical signifi-
cance of measuring the serum GU activity when
dealing with hepatitis C. On the whole, a good
correlation was found between the serum ALT and
serum GU activity, but no correlation was seen in
some cases. When analyzed by disease, the corre-
lation was more marked in patients with HCC or
“other disease” than in patients with CH or LC. When
analyzed by virus type, the correlation tended to
be higher in the HCV group than in the HBV group.
Among patients with LC, the degree of correlation
differed little between the HBV and the HCV groups.
Among patients with CH, the correlation was more
marked in the HBV group, while among patients
with HCC, the correlation was more marked in the
HCV group. In the cases of “other disease” and
NBNC group, they include several different etiologies.
So, the meanings of the differences concerned them
are unknown. Thus, no definitive tendency was ob-
served in this analysis. This suggests that the se-
rum ALT and serum GU activities are not directly
related to the underlying pathology or the patho-
genic virus type, but rather to differences in the
quantum of release of these enzymes from the liver
depending on the underlying pathophysiological
condition.
Takino et al. (16) and Noma et al. (17) have pub-
lished some reports previously regarding the cor-
relation between the serum ALT and serum GU
activity in patients with liver disease. The coefficient
of correlation reported by them is considerably
lower than that obtained in our study. In the study
conducted by Takino et al., a correlation between
the serum ALT and GU activities was observed in
patients with acute hepatitis and CH, but they noted
no correlation between the two in the LC group
(r=0.290). In the study conducted by Noma et al. ,
a correlation was seen in patients with acute hepa-
titis, but not in patients with CH or LC. The low co-
efficient of correlation noted in the studies of Takino
et al. and Noma et al. could probably be attributed
to the conventional method with low sensitivity that
they employed in these studies to determine the
enzyme activities in the serum. In our study, the
coefficient of correlation was higher in the HCC
group and the “other disease” group than in the CH
and the LC groups. These findings suggest that
whether or not the serum ALT activity is correlated
with the serum GU activity depends on the under-
lying pathophysiological condition in each patient.
In our analysis of the cases in whom no correla-
tion was detected between the serum ALT and se-
rum GU activity, the percentage of cases with nor-
mal serum ALT activity but abnormally elevated se-
rum GU activity was significantly lower than the per-
centage of cases in whom the reverse was true. This
finding could be associated with the differences in
tissue distribution between ALT and GU, differences
in the half-lives in the blood of the two enzymes, or
differences in their release from the hepatocytes
depending on the underlying pathophysiological con-
dition. The percentage of cases with normal serum
ALT activity but elevated serum GU activity was
significantly higher in HCV-positive patients with
CH. In both the HBV and the HCV groups, this
percentage tended to increase as CH advanced to
LC or LC advanced to HCC. One factor that could
be responsible for this result is that as liver dis-
ease advances, the serum ALT activity returns to-
wards normal more frequently than serum GU
activity. In the HCV group, the percentage of cases
with abnormally high serum ALT activity but nor-
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mal serum GU activity was significantly higher in
patients with CH than in patients with LC or HCC.
This could be because the release of ALT and GU
into the blood varies depending on the underlying
liver disease.
Of the HCV-positive patients with normal serum
ALT activity, 20.3% had abnormally high GU activ-
ity. Patients with hepatitis C are often asymptomatic
and their serum levels are rarely elevated. It is high-
ly probable that asymptomatic HCV-positive patients
who were ASC, or had CH or LC, donated blood be-
fore the HCV antibody was discovered in this study.
The serum ALT activity was probably normal in many
of these patients, and it would seem that 20% of
these patients could have been detected by serum
GU activity measurement. Therefore, the results ob-
tained by us endorses the view that serum GU mea-
surement could serve as a useful means for screen-
ing blood donated for transfusion.
Overall, a significant correlation was observed
between the serum GU and serum ALT activity in
patients with liver disease. However, because the
release of these enzymes into the blood varies de-
pending on the pathogenic virus type and the under-
lying liver condition, there were cases in which
the serum ALT activity was normal while the se-
rum GU activity was elevated. The percentage of
these cases was high among patients with chronic
hepatitis C. Patients with chronic hepatitis C are
often asymptomatic, and their condition is difficult
to diagnose unless a test for HCV antibody is per-
formed. Before 1989, no method to check for HCV
antibody in the serum was available. It is highly
probable that blood donated by HCV-positive indi-
viduals with normal serum ALT activity were used
for transfusion before 1989. Serum GU activity measure-
ment thus can probably serve as a very useful means
for the screening of blood donated by HCV-positive
individuals with normal ALT activity. The fact that
the incidence of post-transfusion hepatitis decreased
following the introduction of screening of donated
blood for high GU activity implies that this screen-
ing test made it possible to reject blood donated
by patients of hepatitis C with normal serum ALT
activity but elevated serum GU activity.
Conclusion
Serum ALT and GU activities were analyzed in
relation to the pathogenic virus type and the under-
lying liver disease. A significant correlation was ob-
served in all the groups examined between the se-
rum ALT and serum GU activity. However, the de-
gree of this correlation varied, probably because
the release of these enzymes into the blood varies
depending on the type of the pathogenic virus and
the underlying liver disease. The percentage of cases
with normal serum ALT activity but elevated serum
GU activity was high in the HCV group. Before 1989,
no test to check donated blood for HCV antibody
was available. However, screening of donated blood
for high GU activity was associated with a reduced
incidence of post-transfusion hepatitis. This is prob-
ably because following the screening, blood donated
by patients with hepatitis C who had normal serum
ALT activity but elevated serum GU activity was
rejected.
After the introduction of HCV antibody measure-
ment, GU measurement is still useful to reveal the
pathophysiological condition in patients with chron-
ic hepatitis type C.
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